Vistagen Therapeutics Stock Current Valuation
| VTGN Stock | USD 2.93 0.09 2.98% |
Valuation analysis of VistaGen Therapeutics helps investors to measure VistaGen Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 13th of November 2024, Enterprise Value Over EBITDA is likely to drop to -3,364. In addition to that, Enterprise Value Multiple is likely to drop to -3,364. Fundamental drivers impacting VistaGen Therapeutics' valuation include:
Price Book 0.7745 | Enterprise Value -25.2 M | Enterprise Value Ebitda (0.19) | Price Sales 95.9573 | Enterprise Value Revenue 8.0488 |
Undervalued
Today
Please note that VistaGen Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of VistaGen Therapeutics is based on 3 months time horizon. Increasing VistaGen Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since VistaGen Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of VistaGen Stock. However, VistaGen Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.93 | Real 5.24 | Target 12.0 | Hype 2.93 | Naive 2.95 |
The intrinsic value of VistaGen Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VistaGen Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of VistaGen Therapeutics helps investors to forecast how VistaGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VistaGen Therapeutics more accurately as focusing exclusively on VistaGen Therapeutics' fundamentals will not take into account other important factors: VistaGen Therapeutics Company Current Valuation Analysis
VistaGen Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current VistaGen Therapeutics Current Valuation | (25.21 M) |
Most of VistaGen Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VistaGen Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
VistaGen Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for VistaGen Therapeutics is extremely important. It helps to project a fair market value of VistaGen Stock properly, considering its historical fundamentals such as Current Valuation. Since VistaGen Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VistaGen Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VistaGen Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
VistaGen Current Valuation Historical Pattern
Today, most investors in VistaGen Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various VistaGen Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of VistaGen Therapeutics current valuation as a starting point in their analysis.
VistaGen Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, VistaGen Therapeutics has a Current Valuation of (25.21 Million). This is 100.18% lower than that of the Biotechnology sector and 100.54% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.15% higher than that of the company.
VistaGen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VistaGen Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics of similar companies.VistaGen Therapeutics is currently under evaluation in current valuation category among its peers.
VistaGen Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of VistaGen Therapeutics from analyzing VistaGen Therapeutics' financial statements. These drivers represent accounts that assess VistaGen Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of VistaGen Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 19.3M | 183.5M | 245.5M | 25.1M | 22.5M | 21.4M | |
| Enterprise Value | 22.0M | 84.1M | 180.4M | 11.1M | 10.0M | 9.5M |
VistaGen Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, VistaGen Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to VistaGen Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
VistaGen Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (77.74) % | ||||
| Current Valuation | (25.21 M) | ||||
| Shares Outstanding | 27.06 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 57.51 % | ||||
| Number Of Shares Shorted | 528.16 K | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 95.96 X | ||||
| Revenue | 1.06 M | ||||
| Gross Profit | (227.3 K) | ||||
| EBITDA | (33.02 M) | ||||
| Net Income | (29.36 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 2.12 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (25.81 M) | ||||
| Short Ratio | 4.13 X | ||||
| Earnings Per Share | (0.93) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 39 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 84.09 M | ||||
| Total Asset | 123.65 M | ||||
| Retained Earnings | (356.21 M) | ||||
| Working Capital | 115.55 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
| Net Asset | 123.65 M |
About VistaGen Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VistaGen Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VistaGen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VistaGen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
Moving against VistaGen Stock
| 0.7 | DOMH | Dominari Holdings | PairCorr |
| 0.67 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.61 | DNLI | Denali Therapeutics Downward Rally | PairCorr |
| 0.48 | VCYT | Veracyte | PairCorr |
| 0.46 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out VistaGen Therapeutics Piotroski F Score and VistaGen Therapeutics Altman Z Score analysis. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.